Introduction
Retinal vein occlusion (RVO) is a multifactorial microvascular vitreoretinal eye disease, with complex mechanical, hemodynamic, and rheological shear stress, coagulation, as well as biochemical and immunological factors involved in its pathogenesis.
Regarding the pathogenesis of RVO, various proinflammatory cytokines and angiogenic growth factors induced by hypoxia have been implicated in increased microvascular permeability, inflammation, and fibroproliferation by controlling the inner blood-retinal barrier breakdown, extracellular matrix cytoskeletal remodeling, and endothelial-mesenchymal cell transition. Especially, the presence of ischemia-regulated growth factors, such as vascular endothelial growth factor (VEGF) and angiopoietin 2, as well as of matrix metalloproteinases has been implicated in the pathogenesis of RVO [1] .
In adults, pathological angiogenesis and lymphangiogenesis are dynamic hierarchical biological processes related to tissue ischemia/hypoxia in numerous conditions, such as cancer, inflammatory diseases, and various eye disorders [2] [3] [4] [5] [6] [7] [8] . In pathological conditions, the secondary ingrowth of lymphatic vessels can also occur in physiologically alymphatic parts of the eye [7] . In lymphatic vasculature, the differentiating lymphatic endothelial cells (LECs) are known to express lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), podoplanin (PDPN), and prospero-related homeobox protein 1 (Prox-1) [9] [10] [11] , showing phenotypic variation according to anatomic location and functional state. Interestingly, solitary adult blood ECs (BECs) have the capability of clonal expansion, and some of the enddifferentiated, mature vascular wall ECs have the potential to acquire stem cell-like characteristics in vivo in angiogenic disorders by turning on the adult stem/progenitor cell CD117 (c-kit) expression [12] .
In our study, we performed vitrectomy for the management of end-stage hemi-RVO coupled with vitreous hemorrhage (VH), fulminant intraocular neovascularization, and tractional retinal detachment (TRD). We hypothesized that the natural development of hemi-RVO could rely on ischemia-induced lymphatic-like differentiation and adult vascular endothelial stem cell (VESC) proliferation. Therefore, we investigated by immunohistochemistry (IHC) the pathogenesis of RVO-related neovessel formation focusing on multiple known lymphatic markers (LYVE-1, PDPN, and Prox-1), the vascular stem cell marker CD117 (c-kit), and the marker for active cell proliferation Ki67. Our study is considered important since the development of a treatment armamentarium for RVO remains a priority. To develop more effective treatments, it is imperative that we better understand the mechanisms involved in RVO neovessel formation.
The study was conducted according to the principles of the Declaration of Helsinki, and it was approved by the Institutional Review Board of Helsinki University Central Hospital and its Ethical Committee. Signed informed consent was obtained from the participant before inclusion into the study.
We present a 58-year-old Caucasian woman who had hypertension, hyperlipidemia, and hypothyreosis. Her medication included metoprolol, simvastatin, acetylsalicylic acid, and thyroxin. The patient was examined in May 2011 in a private eye hospital when her visual acuity (VA) was still full at 1.0 in both eyes. Thereafter, she did not have regular ophthalmic controls until she developed acute painless central VA loss in her left eye in August 2012. In the private eye hospital, biomicroscopic examination revealed inferior hemi-RVO with macular edema (ME) and minor VH. The patient was admitted to the university eye clinic for laser treatment.
On presentation at the Helsinki University Hospital eye clinic in September 2012, her VA in the left eye had decreased to finger counting at 1 m, with tension measured by applanation tonometry being normal at 13 mm Hg. Her systemic blood pressure was elevated at 189/88 mm Hg. Slit-lamp examination of the anterior segment was normal, and the crystalline lens was clear. On dilated fundus examination, dense VH prevented an examination of the fundus structural details and also prevented documentation with fluorescence angiography and optical coherence tomography. Ocular ultrasonography revealed some elevation in the inferior part of the retina.
In October 2012, the left eye underwent 23-gauge vitrectomy (Constellation Vision System, Alcon Laboratories, Inc., Fort Worth, Tex., USA). Perioperatively, the patient was found to have hemi-RVO with fulminant floating neovessel formation at the optic disc and ME with epiretinal fibrosis membrane situated in the macular area and along the inferior temporal retinal vascular arcade together with neovascularization as well as local TRD (size of 3 disc diameters). The neovessel formation at the optic disc was excised and removed with microforceps (MAXGrip, Alcon Laboratories) for IHC analysis. Epiretinal and internal limiting membrane peeling was performed, and the ischemic inferior retinal hemisphere was laser photocoagulated at 180 degree with confluent spots. Finally, the eye was filled with C3F8 (octafluoropropane) endotamponade, and the patient was seen 1 week after surgery to attach the detached retina.
Postoperatively, at the final follow-up visit in November 2012, the VA was 0.4 on the Snellen chart, and the intraocular pressure was normal at 14 mm Hg. Optical coherence tomography revealed slight cystic ME (270 µm). The inferior temporal retina was fully attached, and the photocoagulation had been well performed. Her right eye was normal, with full 1.0 VA on the Snellen chart and normal fundus details.
Antibodies and Reagents
Rabbit polyclonal antibodies against LYVE-1 (Abcam; 1:100) and Ki67 (NCL-Ki67p, Leica Microsystems; 1:3,000), mouse monoclonal antibodies against CD117 (K45, Thermo Scientific; 1:100), α-SMA (1A4, Sigma-Aldrich; 1:1,000), PDPN (D2-40, Ventana ready-to-use reagent 760-4395, Roche), and CD31 (JC70A, Dako; 1:50), as well as goat polyclonal antibodies against Prox-1 (R&D Systems; 1:40) were used.
Immunohistochemistry
IHC was done essentially as described in our previous report [8] . Briefly, the hemi-RVO neovascular membrane was fixed with 4% paraformaldehyde for 3 h, immediately after sur-gical excision, washed in PBS, dehydrated, and embedded in paraffin. Serial 5-µm sections were cut from each specimen. Standard hematoxylin and eosin (H&E) staining was employed on each first and last section, before and after a series of sections had been cut for IHC staining. For IHC, sections were deparaffinized in TissueClear (Tissue-Tek) and rehydrated in graded ethanol series. Antigen retrieval was performed by boiling the tissue sections in sodium citrate buffer or by treatment with 0.025% trypsin for 30 min at +37°C. Sections were subsequently incubated for 10 min in 0.6% (v/v) hydrogen peroxide. Tissue sections were then rinsed and incubated with blocking buffer (2.5% normal horse serum; Vector Laboratories) for 30 min. Pretitrated dilutions of primary antibodies were incubated for 2 h in blocking buffer, followed by incubation with peroxidase-conjugated anti-mouse Ig or anti-rabbit Ig secondary antibodies for 30 min (α-SMA and CD31) or biotinylated anti-mouse Ig or anti-rabbit Ig secondary antibodies (LYVE-1, Prox-1, CD117, and Ki67). For the staining of LYVE-1, Prox-1, CD117, and Ki67 were incubation with peroxidase-labeled streptavidin (Vectastain; Vector Laboratories) for 30 min. Subsequently, the sections were incubated for 10 min with biotinylated tyramine, followed by a 30-min incubation with peroxidase-labeled streptavidin. Staining was developed by incubation with 3-amino-9-ethyl-carbazole solution (LYVE-1, Prox-1, CD117, and Ki67) or with chromogen substrate diaminobenzidine (Vectastain ABC kit) according to the manufacturer's instructions. After washes, slides were counterstained with hematoxylin (Sigma), dehydrated, and mounted using Cytoseal (for SMA and CD31; Electron Microscopy Sciences) or directly mounted with Aquamount mounting medium (for LYVE-1, Prox-1, and CD117). Immunofluorescence of paraffin sections was performed using Alexa 488 and Alexa 594 conjugated secondary antibodies, counterstained with DAPI, and mounted with Immumount mounting medium. Light micrographs were taken using a Leica DMLB microscope combined with a computer-controlled Olympus digital camera and Studio Lite software. N Plan 5×, BF, 0.12 NA, N Plan 10×, BF, 0.25 NA, N Plan 20×, BF, 0.4 NA, and N Plan 40×, BF, 0.65 NA objectives were used. Epifluorescence micrographs of immunofluorescence staining were obtained using Zeiss Axio Imager Z2 upright epifluorescence microscopes with a Plan-Apochromat 40×, 0.75 NA, objective lens. Postacquisition image processing was performed using Corel Draw software X5. Brightness and contrast were linearly adjusted using Corel Photo-Paint X5.
The IHC slides were independently evaluated under a microscope by four investigators (P.R., E.G., K.L., and P.S.) and an experienced pathologist (J.L.). Five non-diabetic epiretinal or subretinal membranes were used as negative controls and melanoma sections as positive controls for CD31 and LYVE-1, essentially as described in our previous study [8] . In addition, CD31, PDPN, and Prox-1 antibody specificities were confirmed on venolymphatic malformation of the human lip, containing dilated capillaries, small venules, and PDPN-positive slitlike lymphatic capillaries ( fig. 2c ).
Results
First, we examined cellular components and morphological features of the specimen by IHC and histological analysis in light microscopy. Corresponding histological whole-tissue H&E staining showed a fibrotic state, with capillary-like vascular structures (fig. 1a) . The hemi-RVO specimen displayed neovessels lined by a layer of CD31-positive BECs, and these BECs were covered by α-SMA-positive pericytes or smooth muscle cells (fig. 1b ).
Next, we investigated possible lymphatic vessel involvement or potential LEC differentiation by IHC for LEC markers LYVE-1, PDPN, and Prox-1 ( fig. 2) . Lymphatic-like capillary structures stained positive with LYVE-1 antibody (fig. 2a) . Immunoreactivity for PDPN was not found in any vascular structures in our tissue but only outside lumen-like structures, representing potentially inflammatory macrophages or bone marrow-derived cells ( fig. 2a , right inset) [13] .
Interestingly, nuclear staining of lymphatic-specific transcriptional factor Prox-1 was observed in many CD31-positive lumen-lining ECs and adjacent cells (fig. 2b) . Considering the Prox-1 detection also in non-ECs, the specificity of detection was confirmed using venolymphatic malformation of the human lip. As expected, slit-like PDPN-expressing lymphatic capillaries showed positivity for Prox-1 ( fig. 2c) . Notably, coimmunostaining of Prox-1 and Ki67 showed active proliferation of Prox-1-positive lumen-lining cells ( fig. 2d) .
Neovascular Hemi-RVO Specimen Displayed Markers of Endothelial Stem/Progenitor Cells and Active Cell Proliferation
To estimate the extent of the neoangiogenic process and stem cell-like properties in the hemi-RVO tissue, we analyzed the expression of the proliferation marker Ki67 and the stem cell marker CD117 (c-kit; fig. 3 ). CD117 positivity was found in CD31-positive capillaries. With larger magnification, CD117-positive cytoplasmic staining was detected in a large proportion of lumen-lining ECs. Additionally, immunoreactivity for the active proliferation marker Ki67 could be detected both in lumen-lining cells and, extravascularly, in our specimen. Thus, the expression of the stem cell marker CD117 and Ki67 is consistent with VESC activity.
Discussion
This descriptive, morphologic, immunohistochemical study indicates that some intraocular lymphatic-like EC differentiation and VESC activity occur in the end-stage ischemic hemi-RVO neovessel formation. Our unique neovessel specimen was considered to represent the natural outcome of hemi-RVO since no intervening confounding treatment such as laser photocoagulation or intravitreal anti-VEGF agent had been given to the patient before vitreoretinal microsurgery. Our novel findings support the potential involvement of LEC-like endothelial differentiation towards LEC signature together with stem cell activation in RVO pathogenesis, suggesting that the natural antilymphangiogenic mechanisms are overwhelmed in sight-threatening forms of RVO.
By IHC, we could detect both LYVE-1-and Prox-1-positive vessel structures in our hemi-RVO neovessel specimen. We focused on these LEC markers since they were known to most plausibly define the lymphatic vessels versus blood vessels [10, 14] . In our study, the excised hemi-RVO neovessel tissue specimen expressed both the best-characterized LEC marker LYVE-1 as well as the master regulator of lymphatic development, the nuclear transcription factor Prox-1. Thus, the lymphatic-like vessels observed in our hemi-RVO specimen could represent the true development of lymphatic-like vessels, and Prox-1 could serve as the inducer of lymphatic reprogramming of BECs to LECs [6] . Physiologically, lymphatic-like vessels are needed for tissue drainage (homeostasis), metabolism, and immune responses [4] . In pathological fibrovascular RVO eye condition, lymphatic endothelial-like differentiation would occur as a tissue response to growing fluid and metabolic imbalance.
Until now, the potential role of PDPN in pathological lymphangiogenesis in adult vascular RVO has not been well explored. Although, according to previous studies, PDPN is known to be one of the most highly expressed genes in lymphatic endothelium [2] , it was not expressed in lumen-lining ECs in our hemi-RVO tissue sample, but rather in extravascular cells. While PDPN has been reported to be expressed also by e.g. inflammatory macrophages, the identity of these cells, as well as the reason for the lack of luminal PDPN expression, remain subjects for future studies [13] . Probably, the developmental and/or the functional state of our hemi-RVO neovessels could relate to the lack of luminal PDPN expression, suggesting that the lymphatic vessels remained immature [2] . That could explain why our hemi-CRVO tissue specimen did not display all features of terminally differentiated lymphatic endothelium. Interestingly, the same features of PDPN expression were also observed in our previous PDR study [8] .
Notably, neoangiogenic mechanisms seemed to be activated in our hemi-RVO tissue specimen, since CD117 (c-kit) was expressed in the vessel-lining ECs. A previous experimental study had shown that a small subpopulation of CD117-positive ECs have proliferative capacity and the ability to differentiate toward functional ECs in adult blood vessel endothelium [12] . Indeed, according to that study, such a single c-kit-positive VESC could generate in vivo functional blood vessels that are capable of connecting to the host circulation [12] . Even though VESCs were known to display long-term self-renewal capacity, leading to the growth of a greater number of proliferative daughter cells in an experimental study, it was unclear whether this mechanism could be relevant also in advanced ischemic human hemi-RVO. Another possible explanation for our novel finding is that some end-differentiated mature retinal vascular wall ECs of our hemi-RVO eye were able to acquire stem cell-like characteristics in vivo by turning on the CD117 expression [12] .
Our present work contradicts the current understanding that the intraocular posterior part of the human eye is devoid of lymphatics in ischemic hemi-RVO. Our study suggests that also in a severe sight-threatening fibrovascular RVO milieu, the antiangiogenic mechanisms can be overwhelmed and the physiological immune privilege broken, supporting our findings of lymphatic endothelial-like differentiation also in PDR [8] . In our study, the perfused, partially fibrotic neovascular tissue was situated at the optic nerve head. Since our IHC data verified the presence of vessel-like structures that stained with major LEC markers (LYVE-1 and Prox-1), we suggest that LECs might originate through sprouting from retinal venous BECs also in an advanced pathological RVO condition. Alternatively, tissue-resident and recruited circulating bone marrow-derived LEC progenitor cells such as macrophages or mesenchymal precursor cells could participate in the process of lymphatic-like differentiation in our pathological hemi-RVO case. In the future, to further investigate the development of RVO, double staining with LYVE-1+ or Prox-1+ CD68 + macrophages should be performed [15] . Unfortunately, in our study, we only rely on the expression of lymphatic and neoangiogenic markers/antigens, but have no functional data to prove our hypothesis. Unfortunately, no animal model is currently available to easily prove our hypothesis. However, recently, several in vivo and in vitro models of lymphangiogenesis have been developed. A further limitation of our study is that we have only examined one case with hemi-RVO. Therefore, we need to be careful of conclusions which have been based on only one sample. The lack of surgical patients suffering from this disease prevents us from receiving enough representative tissue material for the study.
Presently, it is acknowledged that active angiogenesis in RVO eyes leads to VH, fibrosis formation, and ultimately to TRD, glaucoma, and visual loss. Thus far, the role of the lymphatic-like differentiation process in RVO has not been published. Currently, only limited evidence of efficient treatment options exists for RVO, with intravitreal injections of anti- VEGF agents emerging as a part of the first-line treatment, despite their potential, detrimental, long-term retinal side effects.
Conclusion
Our novel findings suggest that some lymphatic-like differentiation or BEC-to-LEC transdifferentiation occurs in the adult eye with hemi-RVO. This kind of plasticity between mature BEC and LEC phenotypes has been suggested by in vitro analyses more than a decade ago [3] . Our work suggests that the immune privilege in the posterior eye segment is devoid under a very advanced ischemic fibrovascular condition related to hemi-RVO. This finding is of great importance, considering the future treatment modalities for this devastating eye disease. Our current study suggests that in addition to angiogenic mechanisms, lymphatic and neoangiogenic mechanisms seem to be implicated in the hemi-RVO pathophysiology as well, suggesting that current treatment modalities such as anti-VEGF agents are and will not be efficient enough as therapeutic agents, but should potentially include the adjuvant anti-VEGFR-3 agents, since, generally, lymphangiogenesis can be inhibited by blocking the VEGF-C/VEGF-D/VEGFR-3 signaling pathway [5, 16] . Additionally, knowledge of the mechanisms regulating lymphatic-like differentiation and progenitor cell activity would be an important topic of further research in other devastating vitreoretinal ischemic eye disorders, and, therefore, functional in vitro or in vivo studies seem a great necessity in the nearby future as well. Our data also highlight the need to investigate vascular tube morphogenesis with ultrastructural analysis through transmission electron microscopy to unravel mechanisms underlying the pathological vascular hem-and lymphangiogenesis in RVO in more detail. 
